Pfizer, Unilab Prepare For Battle Over Lipitor Patent In The Philippines
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - After patent infringement disputes between Pfizer and Philippines-based generic drug manufacturer United Laboratories (Unilab) over Pfizer's Lipitor patent, a Makati court is expected to decide in January whether Unilab can continue selling its version of Pfizer's anti-cholesterol statin branded as Avamax. The two companies start presenting evidence this month
You may also be interested in...
Philippine Drug Price Controls Pinch Brands And Generics
SHANGHAI - State-mandated price cuts in the Philippines on branded drugs are putting some generics makers in a tight spot. The government price controls, which began in August 2009, have spread swiftly, and the caps affecting commonly prescribed drugs are now pressuring their generic competitors
Philippine Drug Price Controls Pinch Brands And Generics
SHANGHAI - State-mandated price cuts in the Philippines on branded drugs are putting some generics makers in a tight spot. The government price controls, which began in August 2009, have spread swiftly, and the caps affecting commonly prescribed drugs are now pressuring their generic competitors
Korea's Supreme Court Upholds Lower Courts' Ruling against Pfizer's Lipitor Patent Extension
SEOUL - Ending nearly two years of court battles over the patent extension of Pfizer's cholesterol drug Lipitor, South Korea's Supreme Court upheld the lower courts' rulings in favor of six local Korean pharmaceutical companies that have been selling generics of Lipitor (atorvastatin)